tbuckley/cabot-search huggingface dataset:
FRI0629-HPR USE AND USABILITY OF THE DR. BART APP AND ITS RELATION WITH CLINICAL OUTCOMES IN PEOPLE WITH KNEE AND/OR HIP OSTEOARTHRITIS
Authors: T. Pelle, J. Van der Palen, F. Van den Hoogen, K. Bevers, C. Van den Ende
Journal: Annals of the Rheumatic Diseases (2020)

Background: Self-management is of paramount importance in non-surgical treatment of knee and/or hip osteoarthritis(OA). Modern technologies offer the possibility to support self-management 24/7. We developed an e-self-management application (dr. Bart app) for people with knee and/or hip OA. Objectives: To document the use of the dr. Bart app and its relation with health care utilization and clinical outcomes in people with knee and/or hip OA. Methods: For this study we used back end data of the first 26 weeks from the intervention group (N=214) of a RCT (total included 427) examining the effectiveness of the dr. Bart app. Participants were included based on self-reported knee and/or hip OA. In figure 1 the theoretical framework of the dr. Bart app is presented. A central element of the dr. Bart app is that the app proposes a selection of 72 preformulated goals for health behaviours based on the ‘tiny habits method’ 1 (e.g. today I rise 12 times from my chair to train my leg muscles). The proposals are tailored to user characteristics and related to four themes that are core elements in the non-surgical management of OA. After a user completes one or more of the selected goals, a new selection is proposed by dr. Bart. A user can work on 3 goals simultaneously. Goals can be completed more than once by the same user. To assess the association between intensity of use of the app and health care utilization and clinical outcomes, we calculated Spearman rank correlation coefficients. Figure 1. Theoretical framework of the dr. Bart app. Results: 171 / 214 participants (80 %) logged in at least once whilst 151 (71%) chose at least one goal and 114 (53 %) completed at least one goal during the 26 weeks. Of those who chose at least one goal, 56 participants (37 %) continued to log in up to 26 weeks, 12 (8 %) continued to select new goals from the offered goals and 37 (25 %) continued to complete goals (Figure 2). Preformulated goals regarding the themes activity (e.g. performing an exercise from the exercises library of the app) and nutrition (e.g. eat 2 pieces of fruit today) were found to be most popular by users. We found no correlations between intensity of use and health care utilization and clinical outcomes. Figure 2. Percentage of active users (N=151) over time. Conclusion: A considerable proportion of persons with knee and/or hip OA persistently used the app up to 26 weeks. Patients appear to have preferences for goals related to activity and nutrition, rather than for goals related to vitality and education. We found no relation between intensity of use of the dr. Bart app and health care utilization and clinical outcomes. References: [1] Fogg GJ: A behavior model for persuasive design. In: Proceedings of the 4 th international Conference on Persuasive Technology: 2009: ACM; 2009: 40. Disclosure of Interests: None declared
Life‐threatening pathogens in severe/progressive periodontitis: Focal infection risk, future periodontal practice, role of the <i>Periodontology 2000</i>
Authors: Jørgen Slots
Journal: Periodontology 2000 (2020)

Abstract Severe/progressive periodontitis is associated with cardiovascular disease, cancer, Alzheimer’s disease, and dozens of other serious diseases. Herpesviruses are implicated in severe periodontitis and in specific subsets of each of the above systemic diseases. That both periodontitis and herpesviruses are linked to the same nonoral diseases is consistent with a systemic pathogenic role of periodontal herpesviruses. Effective control of periodontitis‐related systemic diseases requires collaboration between dentistry and medicine. Periodontology has emerged as an important preventive medical discipline, and periodontal teaching and practice need to adjust accordingly.
A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes
Authors: Marc Breton, Lauren Kanapka, Roy Beck, Laya Ekhlaspour, Gregory Forlenza, Eda Cengiz, Melissa Schoelwer, Katrina Ruedy, Emily Jost, Lori Carria, Emma Emory, Liana Hsu, Mary Oliveri, Craig Kollman, Betsy Dokken, Stuart Weinzimer, Mark Deboer, Bruce Buckingham, Daniel Cherñavvsky, R. Paul Wadwa, Idcl Trial Research Group, Eric Renard
Journal: New England Journal of Medicine (2020)

A closed-loop system of insulin delivery (also called an artificial pancreas) may improve glycemic outcomes in children with type 1 diabetes.
BIAS: Transparent reporting of biomedical image analysis challenges
Authors: Lena Maier-Hein, Annika Reinke, Michal Kozubek, Anne L. Martel, Tal Arbel, Matthias Eisenmann, Allan Hanbury, Pierre Jannin, Henning Müller, Sinan Onogur, Julio Saez-Rodriguez, Bram van Ginneken, Annette Kopp-Schneider, Bennett A. Landman
Journal: Medical Image Analysis (2020)

The number of biomedical image analysis challenges organized per year is steadily increasing. These international competitions have the purpose of benchmarking algorithms on common data sets, typically to identify the best method for a given problem. Recent research, however, revealed that common practice related to challenge reporting does not allow for adequate interpretation and reproducibility of results. To address the discrepancy between the impact of challenges and the quality (control), the Biomedical Image Analysis ChallengeS (BIAS) initiative developed a set of recommendations for the reporting of challenges. The BIAS statement aims to improve the transparency of the reporting of a biomedical image analysis challenge regardless of field of application, image modality or task category assessed. This article describes how the BIAS statement was developed and presents a checklist which authors of biomedical image analysis challenges are encouraged to include in their submission when giving a paper on a challenge into review. The purpose of the checklist is to standardize and facilitate the review process and raise interpretability and reproducibility of challenge results by making relevant information explicit.
OP0085 Infliximab plus methotrexate improves signs and symptoms in initial non-responders who continue treatment
Authors: E Keystone, K Patel, G Keenan, T Schaible
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> In an international, placebo-controlled, randomised trial, 428 patients with active RA despite methotrexate (MTX) therapy received placebo (i.e. MTX alone) or infliximab at 3 mg/kg or 10 mg/kg every 4 or 8 weeks along with MTX for 102 weeks. In this trial, infliximab plus MTX improved signs and symptoms, inhibited progression of structural damage, and improved physical function compared to MTX alone. <h3>Objectives</h3> To determine if continued treatment with infliximab benefits patients who are not ACR20 responders at week 30. <h3>Methods</h3> Patients who were not responders according to ACR20 criteria at week 30 were identified. Their clinical response to continued treatment was assessed based on ACR-N at the week 54 and week 102 visits. Analysis of variance on the van der Waerden normal scores was used to compare the ACR-N values at these time points. Radiologic response is based on the modified total Sharp score (TSS). <h3>Results</h3> The ACR-N and change in TSS at weeks 30, 54 and 102 are shown in the Table 1. The ACR-N was higher in the infliximab treated groups, compared to the placebo treated group at weeks 54 and 102. The change in TSS was higher at all time points in the placebo group as compared to the infliximab treated groups. <h3>Conclusion</h3> Patients who did not initially benefit from infliximab treatment derived clinical benefit when they continued to be treated long-term. Radiographic benefit was noted over time in all of the infliximab treated groups. The time point at which patients can be categorised as clinical non-responders to infliximab therapy needs further examination.
OP0012 Does helicobacter infection increase the risk of nsaid induced peptic ulceration in patients with rheumatoid arthritis?
Authors: CA Kelly
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Patients with rheumatoid arthritis (RA) frequently develop dyspepsia due to peptic ulceration. There has been conflicting data published on the interactive roles of non steroidal anti inflammatory drugs (NSAIDs) and colonisation of the gastric antrum with Helicobacter pylori. <h3>Objectives</h3> We wished to assess the prevalence of peptic ulceration in dyspeptic RA patients and matched controls. We intended to calculate the relative risks (RR) of NSAID consumption and Helicobacter infection, both singly and in combination. <h3>Methods</h3> We endoscoped 100 dyspeptic patients with RA and 50 age and sex matched controls with dyspepsia but no evidence of RA. We recorded all medication taken over the preceding 6 months and assessed the presence of Helicobacter using a CLO test at endoscopy. <h3>Results</h3> Endoscopic evidence of peptic ulceration was found in 39% of RA patients and 12% of controls. (p &lt; 0.01). Multiple ulcers were significantly commoner in the RA patients (15% v 2%). NSAIDs were used by 60% of RA patients and 22% controls (p &lt; 0.01). Helicobacter was found in 41% of RA patients and 36% of controls (NS). The consumption of NSAIDs conferred a RR of 5.2, while the presence of Helicobacter gave an RR of 2.0 in RA patients. The RR for the combination of NSAID consumption and Helicobacter infection was 12.3. <h3>Conclusion</h3> RA patients have more major and more multiple pathology at endoscopy than age, sex and symptom matched control subjects. This is mainly due to their increased NSAID consumption but is also contributed to by the presence of Helicobacter infection.
Endoscopic removal of a fish bone piercing the bile duct after pancreaticoduodenectomy
Authors: Takuya Ishikawa, Hiroki Kawashima, Eizaburo Ohno, Masanao Nakamura, Suguru Yamada, Masamichi Hayashi, Mitsuhiro Fujishiro
Journal: Endoscopy (2020)

A 67-year-old man was referred to our endoscopy unit by a surgeon for endoscopic removal of a fish bone suspected on computed tomography (CT). The patient was diagnosed with pancreatic cancer 3 years previously and underwent pancreaticoduodenectomy with R0 resection. Follow-up CT revealed a linear radiopaque structure traversing from the bile duct to the right lobe of the liver ([Fig. 1], arrow), suggestive of a fish bone. He experienced vomiting once after eating a deep-fried sandfish 5 days earlier but had been asymptomatic since then. As he had no signs of cholangitis, he was followed on an outpatient basis for a while. However, CT performed 2 months later also indicated residual fish bone in the bile duct, and double-balloon endoscopy (DBE) was performed ([Video 1]).
Improving the Quality of U.S. Health Care — What Will It Take?
Authors: Elizabeth A. McGlynn
Journal: New England Journal of Medicine (2020)

Interview with Dr. Elizabeth McGlynn on why efforts to improve health care quality have often been unsuccessful and where we can go from here. (12:16)Download Despite nearly two decades of experimentation with standardized measurement, public reporting, and reward-and-penalty programs, average quality performance in U.S. health care remains about the same. So what will it take to improve the quality of care?
Abstract 16774: Pericardial Inflammatory Burden is Lower in Women With Recurrent Pericarditis
Authors: Chandra K Ala, Kinjal Banerjee, Kimi Sato, Beni R Verma, Anil Anumandla, Arnav Kumar, Luis C Afonso, Christine Jellis, Rory Hachamovitch, Allan L Klein
Journal: Circulation (2018)

Introduction: Men with pericarditis are admitted twice as more frequently, but women tend to have more complications. Autoimmune disease is more common in women but its impact on the natural history of pericarditis is unknown. Active pericardial inflammation has been quantified using delayed hyperenhancement (DHE) on cardiac magnetic resonance (CMR) imaging but gender differences have not been studied. Hypothesis: We hypothesize that women presenting with recurrent pericarditis have a higher rate of autoimmune etiology. Further, lower admission rates in women may be explained by lower levels of pericardial inflammation. Methods: We included consecutive patients with recurrent pericarditis attending the pericarditis clinic at our institution, who underwent echocardiographic and CMR imaging. Clinical features, etiology, laboratory values including erythrocyte sedimentation rate (ESR) and ultrasensitive C-reactive protein (CRP) were obtained. Echocardiographic and CMR findings including effusion, quantitative and qualitative pericardial DHE were analyzed. DHE was quantified on the short-axis fat suppressed contrast enhanced sequences by contouring the pericardium, measuring the pericardial signal that was more than 6 standard deviations above that of normal septal myocardium taken as the reference. Results: A total of 198 patients were included, with a mean age of 46±14 years and 103 (52%) females. Women were older than men (49±14 vs. 43±14 years, p = 0.002). Women had a higher prevalence of auto-immune diseases (23% vs. 11%, p = 0.017). On presentation, women more frequently had pedal edema and shortness of breath. Women also had higher ESR (median (IQR) 8 (5-17) vs. 5 (3 - 11) mm, p = 0.007), but CRP was not significantly different. There was no difference in pericardial thickening or effusion on echocardiography. However, on CMR, women were found to have lower DHE (median (IQR) 40 (26 - 62) vs. 53 (35 - 88) cm 3 , p = 0.018). There was no difference in time to resolution between genders (median 21.4 vs. 18.9 months, p = 0.28). Conclusions: Autoimmune diseases are a more frequent etiology for women with recurrent pericarditis. Women had less severe pericardial inflammation by DHE. However, the time to resolution was not different.
SAT0088 Cost-benefit analysis of glucosamine sulfate use
Authors: LG Mantovani, A Belisari, C Cristoforetti, G Giacovelli, LC Rovati
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Osteoarthritis (OA) is a disabling and costly disease (see Belisari’s and Mantovani’s abstract). Glucosamine sulfate has shown to be effective in reducing the severity of OA as measured through the Lequesne index (LI). <h3>Objectives</h3> To evaluate the the pharmacoeconomic profile of Glucosamine sulfate in Italy. <h3>Methods</h3> Cost-benefit analysis of glucosamine sulfate use in the context of the Italian society. We compared 2 different pharmacological interventions in OA patients: piroxicam vs. glucosamine sulfate. We considered direct medical costs (e.g. treatment), direct non-medical (e.g. home adaptation, transport, etc.) and indirect (e.g. wage losses) costs. Costs are expressed in Euros 2000. Benefits were measured on the results of a reference randomised clinical trial. They were expressed in terms of LI score reduction, and were turned into monetary terms using the equation estimated in the study by Belisari and Mantovani, which shows a significant association between severity of the disease and costs (higher costs in more severe patients). <h3>Results</h3> Although glucosamine sulfate therapy cost is higher than piroxicam one (81 vs. 33 Euros, the intervention with glucosamine sulfate resulted in a potential net saving of almost 11 Euro/patient in 90 days and 110 Euros/patient in 150 days attributable to its higher efficacy. <h3>Conclusion</h3> Based on our estimates, glucosamine sulfate has a favourable cost benefit profile compared to piroxicam. <h3>Reference</h3> Rovati LC. Osteoarthritis Cartilage 1997;<b>5</b>(Suppl A):72
Biological strategies for the prevention of periodontal disease: Probiotics and vaccines
Authors: Srinivas Rao Myneni, Kristen Brocavich, Howard H Wang
Journal: Periodontology 2000 (2020)

Abstract Probiotics have been considered as an adjunct to prevent and treat a variety of diseases. The ease of administration of probiotics and the fact that no adverse outcomes have been reported in the literature has promoted increasing interest from the research community for this preventive approach in a number of diseases, including periodontal diseases. Several preliminary human clinical trials have been conducted and have yielded promising results. Vaccination is another biological strategy considered for use in the prevention of periodontal diseases. To date, no vaccine trials have been conducted in humans to determine if this strategy would prevent alveolar bone loss or bacterial colonization by target pathogens. Although the available research appears promising, the current body of evidence is incomplete for both strategies. This review attempts to summarize the present status of these 2 biological strategies for the prevention of periodontal diseases.
Weight Management and Healthy Lifestyles
Authors: Katherine D. Hoerster, Kristen Gray, Susan D. Raffa
Journal: JAMA Internal Medicine (2020)

Solja T. Nyberg, PhD; Archana Singh-Manoux, PhD; Jaana Pentti, MSc; Ida E. H. Madsen, PhD; Severine Sabia, PhD; Lars Alfredsson, PhD; Jakob B. Bjorner, MD; Marianne Borritz, PhD; Hermann Burr, PhD; Marcel Goldberg, MD; Katriina Heikkilä, PhD; Markus Jokela, PhD; Anders Knutsson, PhD; Tea Lallukka, PhD; Joni V. Lindbohm, MD; Martin L. Nielsen, PhD; Maria Nordin, PhD; Tuula Oksanen, MD; Jan H. Pejtersen, PhD; Ossi Rahkonen, PhD; Reiner Rugulies, PhD; Martin J. Shipley, MSc; Pyry N. Sipilä, MD; Sari Stenholm, PhD; Sakari Suominen, PhD; Jussi Vahtera, MD; Marianna Virtanen, PhD; Hugo Westerlund, PhD; Marie Zins, MD; Mark Hamer, PhD; G. David Batty, DSc; Mika Kivimäki, PhD
The X-linked retinopathies: Physiological insights, pathogenic mechanisms, phenotypic features and novel therapies
Authors: Samantha R. De Silva, Gavin Arno, Anthony G. Robson, Ana Fakin, Nikolas Pontikos, Moin D. Mohamed, Alan C. Bird, Anthony T. Moore, Michel Michaelides, Andrew R. Webster, Omar A. Mahroo
Journal: Progress in Retinal and Eye Research (2020)

X-linked retinopathies represent a significant proportion of monogenic retinal disease. They include progressive and stationary conditions, with and without syndromic features. Many are X-linked recessive, but several exhibit a phenotype in female carriers, which can help establish diagnosis and yield insights into disease mechanisms. The presence of affected carriers can misleadingly suggest autosomal dominant inheritance. Some disorders (such as RPGR-associated retinopathy) show diverse phenotypes from variants in the same gene and also highlight limitations of current genetic sequencing methods. X-linked disease frequently arises from loss of function, implying potential for benefit from gene replacement strategies. We review X-inactivation and X-linked inheritance, and explore burden of disease attributable to X-linked genes in our clinically and genetically characterised retinal disease cohort, finding correlation between gene transcript length and numbers of families. We list relevant genes and discuss key clinical features, disease mechanisms, carrier phenotypes and novel experimental therapies. We consider in detail the following: RPGR (associated with retinitis pigmentosa, cone and cone-rod dystrophy), RP2 (retinitis pigmentosa), CHM (choroideremia), RS1 (X-linked retinoschisis), NYX (complete congenital stationary night blindness (CSNB)), CACNA1F (incomplete CSNB), OPN1LW/OPN1MW (blue cone monochromacy, Bornholm eye disease, cone dystrophy), GPR143 (ocular albinism), COL4A5 (Alport syndrome), and NDP (Norrie disease and X-linked familial exudative vitreoretinopathy (FEVR)). We use a recently published transcriptome analysis to explore expression by cell-type and discuss insights from electrophysiology. In the final section, we present an algorithm for genes to consider in diagnosing males with non-syndromic X-linked retinopathy, summarise current experimental therapeutic approaches, and consider questions for future research.
Abstract B16: STAT3 promotes ovarian cancer spheroid growth and metastasis
Authors: David F. Walker, Sarah J. Lacroix, Zachary T. Giaccone, David A. Frank, Sarah R. Walker
Journal: Clinical Cancer Research (2020)

Abstract High-grade serous ovarian cancer remains deadly for the majority of woman who are diagnosed every year. The high mortality rate necessitates new treatment options for physicians and patients to consider. To produce new therapies, different signaling pathways that are activated in ovarian cancer need to be identified. In order to mimic the growth of ovarian cancer in the body, 3D culturing systems were used to grow clusters of ovarian cells (spheroids). Comparing gene expression from cells grown in 2D and 3D, we identified the STAT3 signaling pathway as being highly enriched in ovarian spheroids. STAT3 is a transcription factor that is activated by tyrosine phosphorylation. Once phosphorylated, STAT3 dimerizes, translocates to the nucleus, and regulates the expression of many genes involved in cell survival and migration. To determine if STAT3 was activated in 3D growing cells, we analyzed protein from cells grown in 2D and 3D and determined that STAT3 was tyrosine phosphorylated in cells grown in 3D We have found that the increase in STAT3 phosphorylation in 3D grown cells was associated with increased expression of STAT3 target genes. Consistent with this, we found enhanced STAT3 DNA binding to regulatory regions of STAT3 target genes. Recognizing that STAT3 activation is upregulated in 3D, we wanted to know if STAT3 is necessary for growth in 3D. By using siRNA to reduce the expression of STAT3, we were able to hinder the ability for ovarian cancer to grow in 3D. Moreover, reducing the expression of various components in the STAT3 signaling pathway also reduced the growth of ovarian spheroids. One of the major steps in ovarian cancer metastasis is the clearance of mesothelial cells by the cancer cells. To assess the effects of enhanced STAT3 activity in spheroids, we performed a mesothelial clearance assay with spheroids containing and lacking STAT3 expression. We found that ovarian spheroids with reduced STAT3 expression had a decreased ability to metastasize. This suggests that the STAT3 signaling pathway is a critical pathway involved in the growth and metastasis of ovarian cancer spheroids. This raises the possibility of using STAT3 inhibitors by themselves or in conjunction with standard-of-care therapeutics in the treatment of advanced ovarian cancer. Thus, targeting signaling pathways important in 3D growth may be beneficial for the treatment of ovarian cancer. Citation Format: David F. Walker, Sarah J. Lacroix, Zachary T. Giaccone, David A. Frank, Sarah R. Walker. STAT3 promotes ovarian cancer spheroid growth and metastasis [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research; 2019 Sep 13-16, 2019; Atlanta, GA. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(13_Suppl):Abstract nr B16.
Detection of Residual Tumor With 68Ga-Pentixafor PET/CT in a Patient With Waldenström Macroglobulinemia and Concurrent John Cunningham Virus–Related Progressive Multifocal Leukoencephalopathy
Authors: Qingqing Pan, Yaping Luo, Min Qian
Journal: Clinical Nuclear Medicine (2020)

Abstract A 75-year-old man diagnosed with Waldenström macroglobulinemia (WM) complained of neurological symptoms. Baseline 18 F-FDG PET/CT showed diffusely increased radioactivity in the bone marrow and decreased FDG uptake in the right cerebellum. After rituximab-containing immunochemotherapy, the patient had clinically partial response of WM, but the cerebellar lesion was enlarged. Repeated 18 F-FDG PET/CT was similar to the baseline. 68 Ga-pentixafor PET/CT detected residual tumor of WM in occipital bone and cervical lymph nodes, but there was no uptake in the cerebellar lesion. Finally, John Cunningham virus–related progressive multifocal leukoencephalopathy was confirmed.